Atossa Therapeutics Inc (NASDAQ: ATOS) recently disclosed that it had concluded its recruitment process for individuals for its clinical trials in Australia. The recruitment was for developing the second section of phase 1/2a of its recent study.
A recent study of the properties of AT-H201 comprises several doses of units, especially in healthy individuals. Atossa is developing the compound to assist COVID-19 individuals and other respiratory illnesses with a method to inhale without any stress.
The company requires further approval to recruit more people
The company’s chief executive officer, Steven Quay, stated that the recruitment was overseen and approved by the necessary regulatory bodies, such as the ethics committee. Quay further stated that there are still a few authorisations required for the company to recruit their next batch of individuals.
In the previous year, there are several places where Covid-19 cases have increased: these numbers are despite the spread of various forms of vaccines across the globe. In light of the cases, there also exists a requirement to develop drugs, vaccines, and therapies to decrease or eliminate the virus.
How the researchers will conduct the study
Atossa will regulate the first stage of the study with placebo and administer it to an average of 60 healthy respondents or those diagnosed with moderate symptoms of Covid-19. During the announcement, the company revealed that the study would be in four portions; one ascension dose part- a multiple-dose ascension section- a fusion of healthy participants, and a fusion of individuals with COVID 19.
The relevant authoritative bodies will issue the subsequent phases of the study with the necessary consent, including the Australian Human Research Ethics Committee and others. Atossa intends the compound to increase how the lung performs: the compound is also a mixture of two medication patterns created to treat other forms of illnesses.
The Food and Drug Administration issued consent for both drugs, thus blending a distinct pattern for the compound.
The company is among the leading companies in the pharmaceutical industry that recorded various accomplishments, including creating ideal medication in specific fields. These fields include advancements in treating illnesses such as cancer and others.
